论文部分内容阅读
我所1982年以来,就抗人肝癌铁蛋白抗体在肝癌临床上的应用作了较系统的研究,并成功地应用放射性核素标记此抗体对肝癌进行实验与临床治疗。但推广应用受到放射性核素来源、防护等限制,因此需探索抗肿瘤药物与抗体的结合物。氯甲喋呤(MTX)是细胞周期特异性药物,抗癌谱广,因其具有远离喋呤环活性基因的羧基,易与抗体共价结合而较少影响药物活性,常被用于导向化疗的研究,近
Since 1982, we have systematically studied the application of anti-human hepatoma ferritin antibody in the clinical application of liver cancer, and successfully applied radionuclides to label this antibody for experimental and clinical treatment of liver cancer. However, the popularization and application are limited by the sources and protection of radionuclides. Therefore, it is necessary to explore the combination of anti-tumor drugs and antibodies. Chloromethyl-purine (MTX) is a cell cycle-specific drug with a broad spectrum of anti-cancer genes. Because it has a carboxyl group that is far from the purine-loop activity gene, it is easy to covalently bind with antibodies and has less influence on drug activity. It is often used for targeted chemotherapy. Research, near